Comment on: Benchmarking tocilizumab use for giant cell arteritis

It is with great interest we read the editorial on tocilizumab (TCZ) use in giant cell arteritis (GCA) published on 9th May, 2022 by Conway et al [1]. We write to share some of our data to add weight to the views expressed, particularly in relation to use of TCZ beyond one yearin refractory cases with visual involvement

ANCA associated vasculitis subtypes: Response (response to letter)

Many thanks for the opportunity to respond to the interesting letter to the Editor from Merkel, Jayne, and Bekker, with regard to our publication “ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives”.1In the management section of our review article, we highlighted some examples of where “personalized” treatment could be explored further in trials of ANCA associated vasculitis